These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 35100725)

  • 1. Comparison of Somatic and Germline Variant Interpretation in Hereditary Cancer Genes.
    Moody EW; Vagher J; Espinel W; Goldgar D; Hagerty KJ; Gammon A
    JCO Precis Oncol; 2019 Dec; 3():1-8. PubMed ID: 35100725
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Harriman JW; Espinel WF; Vagher J; Gammon A
    JCO Precis Oncol; 2022 Oct; 6():e2100375. PubMed ID: 36201716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Variant Classification: A Comparison of Public Databases and a Commercial Testing Laboratory.
    Gradishar W; Johnson K; Brown K; Mundt E; Manley S
    Oncologist; 2017 Jul; 22(7):797-803. PubMed ID: 28408614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discrepancies between tumor genomic profiling and germline genetic testing.
    Pauley K; Koptiuch C; Greenberg S; Kohlmann W; Jeter J; Colonna S; Werner T; Kinsey C; Gilcrease G; Weis J; Whisenant J; Florou V; Garrido-Laguna I
    ESMO Open; 2022 Aug; 7(4):100526. PubMed ID: 35780590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatic tumor mutations in moderate risk cancer genes: Targets for germline confirmatory testing.
    Llorin H; Graf M; Chun N; Ford J
    Cancer Genet; 2022 Nov; 268-269():22-27. PubMed ID: 36116289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical implications of conflicting variant interpretations in the cancer genetics clinic.
    Zukin E; Culver JO; Liu Y; Yang Y; Ricker CN; Hodan R; Sturgeon D; Kingham K; Chun NM; Rowe-Teeter C; Singh K; Zell JA; Ladabaum U; McDonnell KJ; Ford JM; Parmigiani G; Braun D; Kurian AW; Gruber SB; Idos GE
    Genet Med; 2023 Jul; 25(7):100837. PubMed ID: 37057674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and Confirmation of Potentially Actionable Germline Mutations in Tumor-Only Genomic Sequencing.
    Clark DF; Maxwell KN; Powers J; Lieberman DB; Ebrahimzadeh J; Long JM; McKenna D; Shah P; Bradbury A; Morrissette JJD; Nathanson KL; Domchek SM
    JCO Precis Oncol; 2019; 3():. PubMed ID: 31511844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of Potentially Pathogenic Germline Variants Among Adult Patients in the Philippines With Solid Malignancies Who Underwent Tumor Genomic Profiling.
    Franco PI; Andal JJ; Ang DC; Que FV
    JCO Glob Oncol; 2024 Jun; 10():e2400019. PubMed ID: 38843470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conflicting Interpretation of Genetic Variants and Cancer Risk by Commercial Laboratories as Assessed by the Prospective Registry of Multiplex Testing.
    Balmaña J; Digiovanni L; Gaddam P; Walsh MF; Joseph V; Stadler ZK; Nathanson KL; Garber JE; Couch FJ; Offit K; Robson ME; Domchek SM
    J Clin Oncol; 2016 Dec; 34(34):4071-4078. PubMed ID: 27621404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Li-Fraumeni syndrome: not a straightforward diagnosis anymore-the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis.
    Batalini F; Peacock EG; Stobie L; Robertson A; Garber J; Weitzel JN; Tung NM
    Breast Cancer Res; 2019 Sep; 21(1):107. PubMed ID: 31533767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specifications of the ACMG/AMP variant curation guidelines for the analysis of germline ATM sequence variants.
    Richardson ME; Holdren M; Brannan T; de la Hoya M; Spurdle AB; Tavtigian SV; Young CC; Zec L; Hiraki S; Anderson MJ; Walker LC; McNulty S; Turnbull C; Tischkowitz M; Schon K; Slavin T; Foulkes WD; Cline M; Monteiro AN; Pesaran T; Couch FJ
    Am J Hum Genet; 2024 Nov; 111(11):2411-2426. PubMed ID: 39317201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol.
    Meric-Bernstam F; Brusco L; Daniels M; Wathoo C; Bailey AM; Strong L; Shaw K; Lu K; Qi Y; Zhao H; Lara-Guerra H; Litton J; Arun B; Eterovic AK; Aytac U; Routbort M; Subbiah V; Janku F; Davies MA; Kopetz S; Mendelsohn J; Mills GB; Chen K
    Ann Oncol; 2016 May; 27(5):795-800. PubMed ID: 26787237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Germline mismatch repair gene variants analyzed by universal sequencing in Japanese cancer patients.
    Kiyozumi Y; Matsubayashi H; Horiuchi Y; Higashigawa S; Oishi T; Abe M; Ohnami S; Urakami K; Nagashima T; Kusuhara M; Miyake H; Yamaguchi K
    Cancer Med; 2019 Sep; 8(12):5534-5543. PubMed ID: 31386297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of hereditary cancer gene variant classifications from ClinVar indicates a need for regular reassessment of clinical assertions.
    Davidson AL; Kondrashova O; Leonard C; Wood S; Tudini E; Hollway GE; Pearson JV; Newell F; Spurdle AB; Waddell N
    Hum Mutat; 2022 Dec; 43(12):2054-2062. PubMed ID: 36095262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of locus-specific databases for BRCA1 and BRCA2 variants reveals disparity in variant classification within and among databases.
    Vail PJ; Morris B; van Kan A; Burdett BC; Moyes K; Theisen A; Kerr ID; Wenstrup RJ; Eggington JM
    J Community Genet; 2015 Oct; 6(4):351-9. PubMed ID: 25782689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specifications of the ACMG/AMP variant curation guidelines for the analysis of germline
    Richardson ME; Holdren M; Brannan T; de la Hoya M; Spurdle AB; Tavtigian SV; Young CC; Zec L; Hiraki S; Anderson MJ; Walker LC; McNulty S; Turnbull C; Tischkowitz M; Schon K; Slavin T; Foulkes WD; Cline M; Monteiro AN; Pesaran T; Couch FJ
    medRxiv; 2024 May; ():. PubMed ID: 38854136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Legacy Genetic Testing Results for Cancer Susceptibility: How Common are Conflicting Classifications in a Large Variant Dataset from Multiple Practices?
    Yin K; Liu Y; Lamichhane B; Sandbach JF; Patel G; Compagnoni G; Kanak RH; Rosen B; Ondrula DP; Smith L; Brown E; Gold L; Whitworth P; App C; Euhus D; Semine A; Dwight Lyons S; Lazarte MAC; Parmigiani G; Braun D; Hughes KS
    Ann Surg Oncol; 2020 Jul; 27(7):2212-2220. PubMed ID: 32342295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Background of Colorectal Tumors From Patients With Lynch Syndrome Associated With Germline Variants in PMS2.
    Ten Broeke SW; van Bavel TC; Jansen AML; Gómez-García E; Hes FJ; van Hest LP; Letteboer TGW; Olderode-Berends MJW; Ruano D; Spruijt L; Suerink M; Tops CM; van Eijk R; Morreau H; van Wezel T; Nielsen M
    Gastroenterology; 2018 Sep; 155(3):844-851. PubMed ID: 29758216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883).
    Hauke J; Hahnen E; Schneider S; Reuss A; Richters L; Kommoss S; Heimbach A; Marmé F; Schmidt S; Prieske K; Gevensleben H; Burges A; Borde J; De Gregorio N; Nürnberg P; El-Balat A; Thiele H; Hilpert F; Altmüller J; Meier W; Dietrich D; Kimmig R; Schoemig-Markiefka B; Kast K; Braicu E; Baumann K; Jackisch C; Park-Simon TW; Ernst C; Hanker L; Pfisterer J; Schnelzer A; du Bois A; Schmutzler RK; Harter P
    J Med Genet; 2019 Sep; 56(9):574-580. PubMed ID: 30979843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.